Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
Vincent Yi Sheng Oei
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Siernicka
3Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
4Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Graczyk-Jarzynka
3Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna Julie Hoel
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiwen Yang
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Palacios
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilde Almåsbak
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malgorzata Bajor
3Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Clement
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwig Brandt
5Science for Life Laboratory, Department of Applied Physics, KTH–Royal Institute of Technology, Solna, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Björn Önfelt
5Science for Life Laboratory, Department of Applied Physics, KTH–Royal Institute of Technology, Solna, Sweden.
6Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodie Goodridge
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Winiarska
3Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Radoslaw Zagozdzon
3Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
7Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Olweus
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon-Amund Kyte
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
8Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Johan Malmberg
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
2The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
9Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: k.j.malmberg@medisin.uio.no
DOI: 10.1158/2326-6066.CIR-17-0207 Published April 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Optimization of primary NK-cell redirection by CAR. A, Histogram showing CAR (empty) expression against background in mock (filled) transfected NK cells after various durations of cytokine (IL15) stimulation. B, Representative dot-plot overlays illustrating CAR expression (red) against background from mock (blue)-transfected NK cells over the next 4 days after transfection and different generations of division in culture. C, Summary graphs from two experiments with two donors included in each experiment (n = 4) illustrating CAR expression over 4 days after transfection and various generations of division. D, CAR constructs used in the study. E, Representative histograms showing CAR expression of different constructs. F, Summary graph from two experiments with three donors included in each experiment (n = 6), illustrating CAR expression of different constructs in primary NK cells. G, Representative diagram from 1 of 3 donors illustrating NK-cell KIR and NKG2A repertoire 24 hours after CAR transfection.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Functional analysis of CAR-redirected primary NK cells. A, Representative gating strategy and contour plots to illustrate functional analysis of bulk primary NK cells. B, Summary graphs of six to nine separate experiments (n = 6–12) showing degranulation response against CD19− (P815 and K562) and CD19+ (221.wt and NALM-6) targets in NK cells transfected with HA21 CAR construct. Statistically significant difference between mock- and CAR-transfected cells indicated by black asterisk with underline (n = 12–14). Summary graphs of two separate experiments with three donors (n = 6) showing NK-cell (C) degranulation response and (D) IFNγ+ NK cells against CD19− (P815 and K562) and CD19+ (221.wt and NALM-6) targets across different CAR constructs (n = 15). Summary graphs of nine separate experiments showing (E) degranulation response and (F) IFNγ+ NK cells against CD19− (K562) and CD19+ (221.wt and NALM-6) targets in NK cells transfected with either HA21 or 41BB/ζ CAR construct (n = 12). Statistically significant difference between mock- and CAR-transfected cells indicated by black asterisk with underline. G, Graph showing CAR expression following repeated target or control cells interactions. An arrow indicates when the new pool of target cells was added (n = 4). Experiments were performed three times.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    CAR-redirected NK cells' response to various cell lines according to their differentiation status. A, Representative gating strategy and contour plots to identify NK cells at various differentiation states and their functional response (CD107a and IFNγ). Summary graphs showing (B) NK-cell degranulation response (data from 14 experiments with two to three donors in each experiment, n = 33) and (C) IFNγ release against CD19− HLA-I–deficient (K562) CD19+ HLA-I low (221) and CD19+ HLA-I+ (NALM-6) according to selected stages of NK-cell differentiation (data from six experiments with two to three donors in each experiment, n = 14). Statistically significant difference between mock- and CAR-transfected cells (all subsets combined) as indicated in the legend.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Redirected NK cells harness the functional capacity established by education in its response to CD19+ targets. A, Representative gating strategy to identify single KIR+ educated NK cells and their functional response (CD107a). B, Summary graphs showing degranulation response of mock- or CAR-transfected 2DL3+ (red) and 2DL1+ (blue) NK cells from HLA-C1 or C2 homozygous donors, respectively, against K562, 221, and NALM-6 cells. Statistically significant difference between mock- and CAR-transfected cells indicated by blue and red asterisks for 2DL1 and 2DL3 NK cells, respectively. Statistically significant difference between single 2DL1- and 2DL3-expressing NK cells (without underlines) indicated by black asterisk. Data are aggregated from six experiments (n = 15).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    CAR-redirected NK cells overcome NKG2A inhibition and boost NKG2C activation of adaptive NK cells. A, Representative contour plots illustrating gating strategy to identify NKG2A or NKG2C single receptor expressing NK cells and their response against 221wt (red) or 221.AEH (blue) targets. Representative contour plots of degranulation of NK cells from selected subsets against the two targets. Numbers represent percentage of the population CD107a+. B, Summary graphs showing CAR-redirected NKG2A (left) NKG2C (right) single positive NK cells' degranulation response against 221.wt or 221.AEH cells. Statistically significant difference between mock- and CAR-transfected cells indicated by black asterisk without underline. Statistically significant difference between 221.wt and 221.AEH cells (with underlines) indicated by black asterisk. Data aggregated from four experiments with two to three donors in each experiment (n = 9). C, Representative graph from one donor illustrating degranulation response from conventional or adaptive NK cells with mock or CAR transfection against 221.wt and 221.AEH cells as well as K562 (CD19– NK-cell target) and P815 (mouse cell line).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    CAR-redirected NK cells remain sensitive to KIR-mediated inhibition. From HLA-C1C2 heterozygous donors, (A) representative contour plots illustrating gating strategy to identify 2DL1- or 2DL3-expressing NK cells and their response against 221.C1 (red) or 221.C2 (blue) targets. Numbers represent percentage of the population CD107a+. B, Summary graphs showing mock- or CAR-transfected KIR 2DL3 (C1, left) 2DL1 (C2, right) single positive NK cells' degranulation response against 221.C1 or 221.C2 targets. Data aggregated from three experiments with two to three donors in each experiment (n = 7).

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    NK cells exhibit KIR-mediated inhibition to cell line expressing normal amounts of HLA-I. A, Histogram illustrating HLA-ABC expression from Bjab (center) and ROS-50 (right) against normal B cells (left) derived from PBMC. B, Graphs illustrating mock- or CAR-transfected, single KIR expressing CAR-redirected 2DL3 (C1, left) or 2DL1 (C2, right) NK cells' response to Bjab and ROS-50 cell lines. Donors were all HLA-C1C2 heterozygous and the target are both HLA-C2 homozygous. Data are aggregated from three experiments with two to three donors in each experiment (n = 7).

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Video 1 - Supplementary Video 1. Time-lapse sequence of a serial killer NK cell attacking a cluster of six 221 cells in a 50Ã-50Ã-300 μm3 microwell. The movie plays the same sequence simultaneously side-by-side in fluorescence (left) and bright field (right). The NK cell is shown in blue (in both panels), live targets are shown in green and dead targets in red. At the end of the movie five target cells have been killed. Total imaging time was 4.5 hours with 10 minutes between frames.
PreviousNext
Back to top
Cancer Immunology Research: 6 (4)
April 2018
Volume 6, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
Cancer Immunol Res April 1 2018 (6) (4) 467-480; DOI: 10.1158/2326-6066.CIR-17-0207

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Vincent Yi Sheng Oei, Marta Siernicka, Agnieszka Graczyk-Jarzynka, Hanna Julie Hoel, Weiwen Yang, Daniel Palacios, Hilde Almåsbak, Malgorzata Bajor, Dennis Clement, Ludwig Brandt, Björn Önfelt, Jodie Goodridge, Magdalena Winiarska, Radoslaw Zagozdzon, Johanna Olweus, Jon-Amund Kyte and Karl-Johan Malmberg
Cancer Immunol Res April 1 2018 (6) (4) 467-480; DOI: 10.1158/2326-6066.CIR-17-0207
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Activin A Mediates Radiation-Induced Antitumor Immunity
  • Mechanisms to CD3-Bispecific Antibody Therapy
  • Improved Estimation of T-cell Receptor Repertoire Diversity
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement